c. baigent, et al. on behalf of the sharp investigators lancet 2011;epub 9 june
DESCRIPTION
C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June. Trial Profile. C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June. Baseline demographic features and laboratory measurements by treatment allocation. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June](https://reader035.vdocuments.net/reader035/viewer/2022081516/56813d54550346895da71233/html5/thumbnails/1.jpg)
C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June
![Page 2: C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June](https://reader035.vdocuments.net/reader035/viewer/2022081516/56813d54550346895da71233/html5/thumbnails/2.jpg)
C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June
Trial Profile
![Page 3: C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June](https://reader035.vdocuments.net/reader035/viewer/2022081516/56813d54550346895da71233/html5/thumbnails/3.jpg)
C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June
Baseline demographic features and laboratory measurements by treatment allocation
![Page 4: C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June](https://reader035.vdocuments.net/reader035/viewer/2022081516/56813d54550346895da71233/html5/thumbnails/4.jpg)
C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June
Average use of study simvastatin plus ezetimibe or non-study statin and average change in plasma LDL
cholesterol from baseline, by period of follow-up
![Page 5: C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June](https://reader035.vdocuments.net/reader035/viewer/2022081516/56813d54550346895da71233/html5/thumbnails/5.jpg)
C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June
Life-table plot of effects of allocation to simvastatin plus ezetimibe versus placebo on major atherosclerotic events
![Page 6: C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June](https://reader035.vdocuments.net/reader035/viewer/2022081516/56813d54550346895da71233/html5/thumbnails/6.jpg)
C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June
Major atherosclerotic events subdivided by type
![Page 7: C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June](https://reader035.vdocuments.net/reader035/viewer/2022081516/56813d54550346895da71233/html5/thumbnails/7.jpg)
C. Baigent, et al. Lancet 2011;Epub 9 June
Major atherosclerotic events by baseline
characteristics
χ² tests on 1 degree of freedom
are shown for heterogeneity
between rate ratios within
dichotomous categories and
for trend within other
categories. BP=blood pressure.
MDRD=Modifi ed Diet in
Renal Disease formula.17
GFR=glomerular fi ltration rate
![Page 8: C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June](https://reader035.vdocuments.net/reader035/viewer/2022081516/56813d54550346895da71233/html5/thumbnails/8.jpg)
C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June
Cause-specific and overall mortality
![Page 9: C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June](https://reader035.vdocuments.net/reader035/viewer/2022081516/56813d54550346895da71233/html5/thumbnails/9.jpg)
C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June
Cancer incidence and cancer mortality by site
![Page 10: C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June](https://reader035.vdocuments.net/reader035/viewer/2022081516/56813d54550346895da71233/html5/thumbnails/10.jpg)
C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June
Effects of allocation to simvastatin plus ezetimibe on muscle and hepatobiliary system
![Page 11: C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June](https://reader035.vdocuments.net/reader035/viewer/2022081516/56813d54550346895da71233/html5/thumbnails/11.jpg)
C. Baigent, et al. Lancet 2011;Epub 9 June
Effects of LDL-lowering therapy
on particular vascular outcomes in four trials in patients with chronic kidney disease and 23 trials
in other patients
Data from the Cholesterol Treatment Trialists’ Collaboration. χ² tests are shown for eterogeneity between rate ratios for each outcome in the four trials (4D, ALERT, AURORA, and SHARP) in patients with chronic kidney disease. MI=myocardial infarction. LDL-C=LDL-cholesterol.